UniProt ID | GSK3B_HUMAN | |
---|---|---|
UniProt AC | P49841 | |
Protein Name | Glycogen synthase kinase-3 beta | |
Gene Name | GSK3B | |
Organism | Homo sapiens (Human). | |
Sequence Length | 420 | |
Subcellular Localization | Cytoplasm . Nucleus. Cell membrane. The phosphorylated form shows localization to cytoplasm and cell membrane. The MEMO1-RHOA-DIAPH1 signaling pathway controls localization of the phosphorylated form to the cell membrane. | |
Protein Description | Constitutively active protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules, by phosphorylating and inactivating glycogen synthase (GYS1 or GYS2), EIF2B, CTNNB1/beta-catenin, APC, AXIN1, DPYSL2/CRMP2, JUN, NFATC1/NFATC, MAPT/TAU and MACF1. Requires primed phosphorylation of the majority of its substrates. In skeletal muscle, contributes to insulin regulation of glycogen synthesis by phosphorylating and inhibiting GYS1 activity and hence glycogen synthesis. May also mediate the development of insulin resistance by regulating activation of transcription factors. Regulates protein synthesis by controlling the activity of initiation factor 2B (EIF2BE/EIF2B5) in the same manner as glycogen synthase. In Wnt signaling, GSK3B forms a multimeric complex with APC, AXIN1 and CTNNB1/beta-catenin and phosphorylates the N-terminus of CTNNB1 leading to its degradation mediated by ubiquitin/proteasomes. Phosphorylates JUN at sites proximal to its DNA-binding domain, thereby reducing its affinity for DNA. Phosphorylates NFATC1/NFATC on conserved serine residues promoting NFATC1/NFATC nuclear export, shutting off NFATC1/NFATC gene regulation, and thereby opposing the action of calcineurin. Phosphorylates MAPT/TAU on 'Thr-548', decreasing significantly MAPT/TAU ability to bind and stabilize microtubules. MAPT/TAU is the principal component of neurofibrillary tangles in Alzheimer disease. Plays an important role in ERBB2-dependent stabilization of microtubules at the cell cortex. Phosphorylates MACF1, inhibiting its binding to microtubules which is critical for its role in bulge stem cell migration and skin wound repair. Probably regulates NF-kappa-B (NFKB1) at the transcriptional level and is required for the NF-kappa-B-mediated anti-apoptotic response to TNF-alpha (TNF/TNFA). Negatively regulates replication in pancreatic beta-cells, resulting in apoptosis, loss of beta-cells and diabetes. Through phosphorylation of the anti-apoptotic protein MCL1, may control cell apoptosis in response to growth factors deprivation. Phosphorylates MUC1 in breast cancer cells, decreasing the interaction of MUC1 with CTNNB1/beta-catenin. Is necessary for the establishment of neuronal polarity and axon outgrowth. Phosphorylates MARK2, leading to inhibit its activity. Phosphorylates SIK1 at 'Thr-182', leading to sustain its activity. Phosphorylates ZC3HAV1 which enhances its antiviral activity. Phosphorylates SNAI1, leading to its BTRC-triggered ubiquitination and proteasomal degradation. Phosphorylates SFPQ at 'Thr-687' upon T-cell activation. Phosphorylates NR1D1 st 'Ser-55' and 'Ser-59' and stabilizes it by protecting it from proteasomal degradation. Regulates the circadian clock via phosphorylation of the major clock components including ARNTL/BMAL1, CLOCK and PER2. Phosphorylates CLOCK AT 'Ser-427' and targets it for proteasomal degradation. Phosphorylates ARNTL/BMAL1 at 'Ser-17' and 'Ser-21' and primes it for ubiquitination and proteasomal degradation. Phosphorylates OGT at 'Ser-3' or 'Ser-4' which positively regulates its activity. Phosphorylates MYCN in neuroblastoma cells which may promote its degradation. [PubMed: 24391509] | |
Protein Sequence | MSGRPRTTSFAESCKPVQQPSAFGSMKVSRDKDGSKVTTVVATPGQGPDRPQEVSYTDTKVIGNGSFGVVYQAKLCDSGELVAIKKVLQDKRFKNRELQIMRKLDHCNIVRLRYFFYSSGEKKDEVYLNLVLDYVPETVYRVARHYSRAKQTLPVIYVKLYMYQLFRSLAYIHSFGICHRDIKPQNLLLDPDTAVLKLCDFGSAKQLVRGEPNVSYICSRYYRAPELIFGATDYTSSIDVWSAGCVLAELLLGQPIFPGDSGVDQLVEIIKVLGTPTREQIREMNPNYTEFKFPQIKAHPWTKVFRPRTPPEAIALCSRLLEYTPTARLTPLEACAHSFFDELRDPNVKLPNGRDTPALFNFTTQELSSNPPLATILIPPHARIQAAASTPTNATAASDANTGDRGQTNNAASASASNST | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
2 | Acetylation | ------MSGRPRTTS ------CCCCCCCCC | 43.43 | 19413330 | |
2 | Phosphorylation | ------MSGRPRTTS ------CCCCCCCCC | 43.43 | 26074081 | |
7 | Phosphorylation | -MSGRPRTTSFAESC -CCCCCCCCCHHHHC | 29.49 | 23927012 | |
8 | Phosphorylation | MSGRPRTTSFAESCK CCCCCCCCCHHHHCC | 24.11 | 22322096 | |
9 | Phosphorylation | SGRPRTTSFAESCKP CCCCCCCCHHHHCCC | 23.11 | 16940331 | |
13 | Phosphorylation | RTTSFAESCKPVQQP CCCCHHHHCCCCCCC | 24.82 | 22322096 | |
15 (in isoform 2) | Ubiquitination | - | 58.46 | - | |
15 | Acetylation | TSFAESCKPVQQPSA CCHHHHCCCCCCCCC | 58.46 | 25953088 | |
15 | Ubiquitination | TSFAESCKPVQQPSA CCHHHHCCCCCCCCC | 58.46 | - | |
21 | Phosphorylation | CKPVQQPSAFGSMKV CCCCCCCCCCCCEEE | 31.71 | 23927012 | |
25 | Phosphorylation | QQPSAFGSMKVSRDK CCCCCCCCEEEEECC | 14.69 | 23401153 | |
27 | Ubiquitination | PSAFGSMKVSRDKDG CCCCCCEEEEECCCC | 38.46 | - | |
27 | Methylation | PSAFGSMKVSRDKDG CCCCCCEEEEECCCC | 38.46 | - | |
29 | Phosphorylation | AFGSMKVSRDKDGSK CCCCEEEEECCCCCE | 29.28 | 26074081 | |
35 | Phosphorylation | VSRDKDGSKVTTVVA EEECCCCCEEEEEEE | 33.80 | 21601212 | |
36 | Ubiquitination | SRDKDGSKVTTVVAT EECCCCCEEEEEEEC | 49.48 | - | |
38 | O-linked_Glycosylation | DKDGSKVTTVVATPG CCCCCEEEEEEECCC | 20.01 | 28510447 | |
39 | O-linked_Glycosylation | KDGSKVTTVVATPGQ CCCCEEEEEEECCCC | 18.90 | 28510447 | |
43 | Phosphorylation | KVTTVVATPGQGPDR EEEEEEECCCCCCCC | 19.15 | 16039586 | |
43 | O-linked_Glycosylation | KVTTVVATPGQGPDR EEEEEEECCCCCCCC | 19.15 | 28510447 | |
55 | Phosphorylation | PDRPQEVSYTDTKVI CCCCCEEEEEEEEEE | 22.89 | 29496907 | |
56 | Phosphorylation | DRPQEVSYTDTKVIG CCCCEEEEEEEEEEC | 17.51 | 29438985 | |
59 | Phosphorylation | QEVSYTDTKVIGNGS CEEEEEEEEEECCCC | 21.29 | 21601212 | |
66 | Phosphorylation | TKVIGNGSFGVVYQA EEEECCCCCEEEEEE | 23.87 | 28348404 | |
71 | Phosphorylation | NGSFGVVYQAKLCDS CCCCEEEEEEEECCC | 10.59 | 25147952 | |
78 | Phosphorylation | YQAKLCDSGELVAIK EEEEECCCCCEEEHH | 32.92 | 30622161 | |
85 | Ubiquitination | SGELVAIKKVLQDKR CCCEEEHHHHHHCCC | 27.39 | - | |
86 | Ubiquitination | GELVAIKKVLQDKRF CCEEEHHHHHHCCCC | 41.90 | - | |
86 (in isoform 2) | Ubiquitination | - | 41.90 | - | |
103 | Ubiquitination | RELQIMRKLDHCNIV HHHHHHHHCCCCCEE | 40.67 | - | |
114 | Phosphorylation | CNIVRLRYFFYSSGE CCEEEEEEEEECCCC | 11.57 | - | |
117 | Phosphorylation | VRLRYFFYSSGEKKD EEEEEEEECCCCCCC | 7.63 | - | |
147 | Phosphorylation | YRVARHYSRAKQTLP HHHHHHHHHHHCCCH | 21.45 | - | |
183 (in isoform 2) | Ubiquitination | - | 44.85 | - | |
183 | Ubiquitination | GICHRDIKPQNLLLD CEECCCCCCHHEECC | 44.85 | - | |
197 (in isoform 2) | Ubiquitination | - | 40.23 | - | |
197 | Ubiquitination | DPDTAVLKLCDFGSA CCCCHHHHHCCCCCH | 40.23 | - | |
203 | Phosphorylation | LKLCDFGSAKQLVRG HHHCCCCCHHHHHCC | 32.08 | - | |
205 | Ubiquitination | LCDFGSAKQLVRGEP HCCCCCHHHHHCCCC | 45.95 | - | |
205 (in isoform 2) | Ubiquitination | - | 45.95 | - | |
205 | Acetylation | LCDFGSAKQLVRGEP HCCCCCHHHHHCCCC | 45.95 | 55837983 | |
215 | Phosphorylation | VRGEPNVSYICSRYY HCCCCCHHHHHCCCC | 18.54 | 29255136 | |
216 | Phosphorylation | RGEPNVSYICSRYYR CCCCCHHHHHCCCCC | 11.15 | 19664994 | |
219 | Phosphorylation | PNVSYICSRYYRAPE CCHHHHHCCCCCCCC | 17.48 | 23927012 | |
221 | Phosphorylation | VSYICSRYYRAPELI HHHHHCCCCCCCCHH | 4.88 | 28152594 | |
222 | Phosphorylation | SYICSRYYRAPELIF HHHHCCCCCCCCHHC | 10.13 | 28152594 | |
275 | Phosphorylation | EIIKVLGTPTREQIR HHHHHHCCCCHHHHH | 19.82 | 17192257 | |
277 | Phosphorylation | IKVLGTPTREQIREM HHHHCCCCHHHHHHH | 46.83 | 17192257 | |
288 | Phosphorylation | IREMNPNYTEFKFPQ HHHHCCCCCCCCCCC | 14.65 | 27642862 | |
292 | Sumoylation | NPNYTEFKFPQIKAH CCCCCCCCCCCCCCC | 50.32 | - | |
292 (in isoform 2) | Ubiquitination | - | 50.32 | 21890473 | |
292 (in isoform 1) | Ubiquitination | - | 50.32 | 21890473 | |
292 | Ubiquitination | NPNYTEFKFPQIKAH CCCCCCCCCCCCCCC | 50.32 | 2189047 | |
292 | Sumoylation | NPNYTEFKFPQIKAH CCCCCCCCCCCCCCC | 50.32 | - | |
297 | Ubiquitination | EFKFPQIKAHPWTKV CCCCCCCCCCCCCCC | 35.08 | - | |
297 (in isoform 2) | Ubiquitination | - | 35.08 | 21890473 | |
297 (in isoform 1) | Ubiquitination | - | 35.08 | 21890473 | |
317 | S-nitrosylation | PPEAIALCSRLLEYT CHHHHHHHHHHHHHC | 1.32 | 2212679 | |
323 | Phosphorylation | LCSRLLEYTPTARLT HHHHHHHHCCCCCCC | 20.28 | 28102081 | |
324 | Phosphorylation | CSRLLEYTPTARLTP HHHHHHHCCCCCCCH | 12.56 | 28102081 | |
349 | Ubiquitination | ELRDPNVKLPNGRDT HHCCCCCCCCCCCCC | 65.94 | - | |
362 (in isoform 2) | Ubiquitination | - | 6.48 | - | |
368 | Phosphorylation | NFTTQELSSNPPLAT EECHHHHHCCCCCEE | 27.58 | 21601212 | |
369 | Phosphorylation | FTTQELSSNPPLATI ECHHHHHCCCCCEEE | 67.01 | 21601212 | |
389 | Phosphorylation | ARIQAAASTPTNATA HHHHHHHCCCCCCCC | 30.14 | 25159151 | |
390 | Phosphorylation | RIQAAASTPTNATAA HHHHHHCCCCCCCCC | 29.43 | 25159151 | |
392 | Phosphorylation | QAAASTPTNATAASD HHHHCCCCCCCCCCC | 37.26 | 25159151 | |
395 | Phosphorylation | ASTPTNATAASDANT HCCCCCCCCCCCCCC | 25.48 | 21712546 | |
398 | Phosphorylation | PTNATAASDANTGDR CCCCCCCCCCCCCCC | 34.49 | 21601212 | |
402 | Phosphorylation | TAASDANTGDRGQTN CCCCCCCCCCCCCCC | 42.03 | 21712546 | |
403 | Phosphorylation | AASDANTGDRGQTNN CCCCCCCCCCCCCCC | 23.56 | 24719451 | |
405 | Phosphorylation | SDANTGDRGQTNNAA CCCCCCCCCCCCCCH | 40.23 | - | |
408 | Phosphorylation | NTGDRGQTNNAASAS CCCCCCCCCCCHHHH | 33.01 | 30177828 | |
413 | Phosphorylation | GQTNNAASASASNST CCCCCCHHHHCCCCC | 21.98 | 18691976 | |
415 | Phosphorylation | TNNAASASASNST-- CCCCHHHHCCCCC-- | 29.72 | 18691976 | |
417 | Phosphorylation | NAASASASNST---- CCHHHHCCCCC---- | 28.90 | 19060867 | |
419 | Phosphorylation | ASASASNST------ HHHHCCCCC------ | 32.76 | 18691976 | |
420 | Phosphorylation | SASASNST------- HHHCCCCC------- | 47.05 | 25262027 | |
426 | Phosphorylation | ST------------- CC------------- | - | ||
428 | Phosphorylation | --------------- --------------- | - | ||
432 | Phosphorylation | ------------------- ------------------- | - |
Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
---|---|---|---|---|---|---|
9 | S | Phosphorylation | Kinase | AURKA | O14965 | GPS |
9 | S | Phosphorylation | Kinase | RSK_GROUP | - | PhosphoELM |
9 | S | Phosphorylation | Kinase | PKA_GROUP | - | PhosphoELM |
9 | S | Phosphorylation | Kinase | RSK-SUBFAMILY | - | GPS |
9 | S | Phosphorylation | Kinase | PKA-FAMILY | - | GPS |
9 | S | Phosphorylation | Kinase | SGK3 | Q96BR1 | Uniprot |
9 | S | Phosphorylation | Kinase | MAP4K5 | Q9Y4K4 | GPS |
9 | S | Phosphorylation | Kinase | RPS6KB2 | Q9UBS0 | GPS |
9 | S | Phosphorylation | Kinase | P70S6K ISO2 | P23443-2 | PSP |
9 | S | Phosphorylation | Kinase | RPS6KB1 | P23443 | GPS |
9 | S | Phosphorylation | Kinase | RSK2 | P51812 | PSP |
9 | S | Phosphorylation | Kinase | RPS6KA1 | Q15418 | GPS |
9 | S | Phosphorylation | Kinase | PRKCZ | Q05513 | GPS |
9 | S | Phosphorylation | Kinase | PRKCH | P24723 | GPS |
9 | S | Phosphorylation | Kinase | PRKCG | P05129 | GPS |
9 | S | Phosphorylation | Kinase | PRKCD | Q05655 | GPS |
9 | S | Phosphorylation | Kinase | PKCB ISO2 | P05771-2 | PSP |
9 | S | Phosphorylation | Kinase | PRKCB | P05771 | GPS |
9 | S | Phosphorylation | Kinase | PRKCA | P17252 | GPS |
9 | S | Phosphorylation | Kinase | AKT1 | P31749 | Uniprot |
9 | S | Phosphorylation | Kinase | PRKACA | P17612 | GPS |
21 | S | Phosphorylation | Kinase | SGK_GROUP | - | PhosphoELM |
21 | S | Phosphorylation | Kinase | SGK-FAMILY | - | GPS |
43 | T | Phosphorylation | Kinase | P38A | Q16539 | PSP |
43 | T | Phosphorylation | Kinase | MAPK3 | P27361 | GPS |
43 | T | Phosphorylation | Kinase | MAPK1 | P28482 | GPS |
56 | Y | Phosphorylation | Kinase | MET | P08581 | PSP |
147 | S | Phosphorylation | Kinase | PRKCZ | Q05513 | GPS |
216 | Y | Phosphorylation | Kinase | MAP2K1 | Q02750 | GPS |
216 | Y | Phosphorylation | Kinase | GSK3B | Q9WV60 | PSP |
216 | Y | Phosphorylation | Kinase | GSK3B | P49841-2 | GPS |
216 | Y | Phosphorylation | Kinase | GSK3B | P49841 | PSP |
389 | S | Phosphorylation | Kinase | MAPK14 | Q16539 | GPS |
390 | T | Phosphorylation | Kinase | MAPK14 | Q16539 | GPS |
- | K | Ubiquitination | E3 ubiquitin ligase | BTRC | Q9Y297 | PMID:24451375 |
- | K | Ubiquitination | E3 ubiquitin ligase | SMURF2 | Q9HAU4 | PMID:22199232 |
Modified Location | Modified Residue | Modification | Function | Reference |
---|---|---|---|---|
9 | S | Phosphorylation |
| 7980435 |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of GSK3B_HUMAN !! |
Kegg Disease | |
---|---|
There are no disease associations of PTM sites. | |
OMIM Disease | |
There are no disease associations of PTM sites. | |
Kegg Drug | |
There are no disease associations of PTM sites. | |
DrugBank | |
DB01356 | Lithium |
loading...
Phosphorylation | |
Reference | PubMed |
"Large-scale proteomics analysis of the human kinome."; Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,Mann M., Daub H.; Mol. Cell. Proteomics 8:1751-1764(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-7; SER-9; SER-25;SER-215; TYR-216; SER-219; THR-275; THR-277; SER-389; THR-390;THR-392; SER-398; SER-413; SER-415; SER-417 AND SER-419, AND MASSSPECTROMETRY. | |
"Lys-N and trypsin cover complementary parts of the phosphoproteome ina refined SCX-based approach."; Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,Mohammed S.; Anal. Chem. 81:4493-4501(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-389, AND MASSSPECTROMETRY. | |
"Kinase-selective enrichment enables quantitative phosphoproteomics ofthe kinome across the cell cycle."; Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,Greff Z., Keri G., Stemmann O., Mann M.; Mol. Cell 31:438-448(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-9; TYR-216; SER-219;THR-275; THR-277; THR-390 AND THR-392, AND MASS SPECTROMETRY. | |
"Proteomics analysis of protein kinases by target class-selectiveprefractionation and tandem mass spectrometry."; Wissing J., Jaensch L., Nimtz M., Dieterich G., Hornberger R.,Keri G., Wehland J., Daub H.; Mol. Cell. Proteomics 6:537-547(2007). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-9; TYR-216 AND THR-390,AND MASS SPECTROMETRY. | |
"Human serum and glucocorticoid-inducible kinase-like kinase (SGKL)phosphorylates glycogen syntheses kinase 3 beta (GSK-3beta) at serine-9 through direct interaction."; Dai F., Yu L., He H., Chen Y., Yu J., Yang Y., Xu Y., Ling W.,Zhao S.; Biochem. Biophys. Res. Commun. 293:1191-1196(2002). Cited for: PHOSPHORYLATION AT SER-9 BY SGK3, AND INTERACTION WITH SGK3. | |
"Inactivation of glycogen synthase kinase-3 beta by phosphorylation:new kinase connections in insulin and growth-factor signalling."; Sutherland C., Leighton I.A., Cohen P.; Biochem. J. 296:15-19(1993). Cited for: PHOSPHORYLATION AT SER-9. | |
"A quantitative atlas of mitotic phosphorylation."; Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,Elledge S.J., Gygi S.P.; Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-216 AND THR-390, ANDMASS SPECTROMETRY. | |
"Large-scale characterization of HeLa cell nuclear phosphoproteins."; Beausoleil S.A., Jedrychowski M., Schwartz D., Elias J.E., Villen J.,Li J., Cohn M.A., Cantley L.C., Gygi S.P.; Proc. Natl. Acad. Sci. U.S.A. 101:12130-12135(2004). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-390, AND MASSSPECTROMETRY. | |
"Structural basis for recruitment of glycogen synthase kinase 3beta tothe axin-APC scaffold complex."; Dajani R., Fraser E., Roe S.M., Yeo M., Good V.M., Thompson V.,Dale T.C., Pearl L.H.; EMBO J. 22:494-501(2003). Cited for: X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 35-384 IN COMPLEX WITH AXIN1,INTERACTION WITH AXIN1 AND FRAT1, FUNCTION, ENZYME REGULATION, ANDPHOSPHORYLATION AT TYR-216. | |
"An extensive survey of tyrosine phosphorylation revealing new sitesin human mammary epithelial cells."; Heibeck T.H., Ding S.-J., Opresko L.K., Zhao R., Schepmoes A.A.,Yang F., Tolmachev A.V., Monroe M.E., Camp D.G. II, Smith R.D.,Wiley H.S., Qian W.-J.; J. Proteome Res. 8:3852-3861(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-216, AND MASSSPECTROMETRY. | |
"Phosphoproteome of resting human platelets."; Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,Schuetz C., Walter U., Gambaryan S., Sickmann A.; J. Proteome Res. 7:526-534(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-216, AND MASSSPECTROMETRY. | |
"Multiple reaction monitoring for robust quantitative proteomicanalysis of cellular signaling networks."; Wolf-Yadlin A., Hautaniemi S., Lauffenburger D.A., White F.M.; Proc. Natl. Acad. Sci. U.S.A. 104:5860-5865(2007). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-216, AND MASSSPECTROMETRY. | |
"Global survey of phosphotyrosine signaling identifies oncogenickinases in lung cancer."; Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J.,Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L.,Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J.,Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X.,Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.; Cell 131:1190-1203(2007). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-216, AND MASSSPECTROMETRY. | |
"A probability-based approach for high-throughput proteinphosphorylation analysis and site localization."; Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; Nat. Biotechnol. 24:1285-1292(2006). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-216, AND MASSSPECTROMETRY. | |
"Global, in vivo, and site-specific phosphorylation dynamics insignaling networks."; Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,Mann M.; Cell 127:635-648(2006). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-216, AND MASSSPECTROMETRY. | |
"Immunoaffinity profiling of tyrosine phosphorylation in cancercells."; Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,Zha X.-M., Polakiewicz R.D., Comb M.J.; Nat. Biotechnol. 23:94-101(2005). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-216, AND MASSSPECTROMETRY. | |
"Time-resolved mass spectrometry of tyrosine phosphorylation sites inthe epidermal growth factor receptor signaling network reveals dynamicmodules."; Zhang Y., Wolf-Yadlin A., Ross P.L., Pappin D.J., Rush J.,Lauffenburger D.A., White F.M.; Mol. Cell. Proteomics 4:1240-1250(2005). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-216, AND MASSSPECTROMETRY. |